The Clozapine Risk Evaluation and Mitigation Strategy (REMS) Program Modification

This resource was selected by SMI Adviser content partners and approved by the SMI Adviser clinical expert team for inclusion in the knowledge base.

The Clozapine Product Manufacturers’ Group (CPMG) and the U.S. Food and Drug Administration (FDA) continue to work to ensure that patients relying on clozapine have continued access to this medication and appropriate management of associated risks. As a result of this work, a modification to Clozapine REMS Program became effective on February 28, 2019.

ACCESS THIS RESOURCE

  • Was this Helpful ?
  • YesNo

Join our #MissionForBetter now

Sign up for our newsletter. We’ll let you know about new resources, education, and more.

Saved Posts

X